Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Circulating Tumor DNA for Cancer Patient Follow-Up: From Technological to...
share announcement

Circulating Tumor DNA for Cancer Patient Follow-Up: From Technological to Clinical Perspectives

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Biomarkers".

Deadline for manuscript submissions: closed (15 August 2022) | Viewed by 4484

Special Issue Editors

Dr. Leonor Benhaim

E-Mail Website
Guest Editor
1. Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Equipe Labellisée Ligue Nationale Contre le Cancer, CNRS SNC 5096, 15 Rue de L'école de Médecine, 75006 Paris, France
2. Department of Visceral and Surgical Oncology, Gustave Roussy, Villejuif, France,114 Rue Edouard-Vaillant, 94805 Villejuif, France
Interests: circulating tumor DNA; digital-droplet PCR; translational research; microfluidics; personalized medicine; cancer; biomarkers; therapeutic optimization; liquid biopsy; NGS
Dr. Valerie Taly

E-Mail Website
Guest Editor
Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Equipe Labellisée Ligue Nationale Contre le Cancer, CNRS SNC 5096, 15 Rue de L'école de Médecine, 75006 Paris, France
Interests: circulating tumor DNA; digital-droplet PCR; translational research; microfluidics; personalized medicine; cancer; biomarkers; therapeutic optimization; liquid biopsy; NGS

Special Issue Information

Dear Colleagues,

In recent years, there has been an increased interest in the use of circulating tumor DNA (ctDNA) for detection, prognosis, and predictive value in cancer treatment. Liquid biopsy approaches based on the detection of ctDNA allow sequential tumor sampling and real-time monitoring providing information on cancer evolution (with or without treatment). More accessible than invasive biopsies, it enables rapid and personalized treatment adaptation.

These developments have been greatly facilitated by technological developments that have allowed us to achieve unprecedented sensitivity. Today, the large diffusion in clinical practice mainly depends on the results of large ongoing clinical trials. It also requires defining specific and precise guidelines for both pre-analytical sample treatments and technical validation. Finally, the impact of technical costs must be considered before approval of specific techniques.

In this Special Issue on “Circulating Tumor DNA for Cancer Patient Follow-Up: From Technological to Clinical Perspectives”, we aim to cover all the aspects of ctDNA detection ranging from the development and validation of pre-analytical conditions and technologies to the presentation of current and future clinical applications of ctDNA. We welcome articles on all aspects of ctDNA detection in solid tumors, from research to clinical applications.

Dr. Leonor Benhaim
Dr. Valerie Taly
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • circulating tumor DNA
  • digital-droplet PCR
  • translational research
  • microfluidics
  • personalized medicine
  • cancer
  • biomarkers
  • therapeutic optimization
  • liquid biopsy
  • NGS

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

19 pages, 26496 KiB  
Article
Circulating Tumor DNA: Less Invasive, More Representative Method to Unveil the Genomic Landscape of Newly Diagnosed Multiple Myeloma Than Bone Marrow Aspirates
by Yang Liu, Jiapei Guo, Yuting Yi, Xuan Gao, Lei Wen, Wenbing Duan, Zhaohong Wen, Yaoyao Liu, Yanfang Guan, Xuefeng Xia, Ling Ma, Rong Fu, Lihong Liu, Xiaojun Huang, Qing Ge and Jin Lu
Cancers 2022, 14(19), 4914; https://doi.org/10.3390/cancers14194914 - 7 Oct 2022
Cited by 2 | Viewed by 1730
Abstract
Multiple myeloma (MM) is highly heterogenous and dynamic in its genomic abnormalities. Capturing a representative image of these alterations is essential in understanding the molecular pathogenesis and progression of the disease but was limited by single-site invasive bone marrow (BM) biopsy-based genomics studies. [...] Read more.
Multiple myeloma (MM) is highly heterogenous and dynamic in its genomic abnormalities. Capturing a representative image of these alterations is essential in understanding the molecular pathogenesis and progression of the disease but was limited by single-site invasive bone marrow (BM) biopsy-based genomics studies. We compared the mutational landscapes of circulating tumor DNA (ctDNA) and BM in 82 patients with newly diagnosed MM. A 413-gene panel was used in the sequencing. Our results showed that more than 70% of MM patients showed one or more genes with somatic mutations and at least half of the mutated genes were shared between ctDNA and BM samples. Compared to the BM samples, ctDNA exhibited more types of driver mutations in the shared driver genes, higher numbers of uniquely mutated genes and subclonal clusters, more translocation-associated mutations, and higher frequencies of mutated genes enriched in the transcriptional regulation pathway. Multivariate Cox analysis showed that age, ctDNA mutations in the transcriptional regulation pathway and DNA repair pathway were independent predictors of progression-free survival (PFS). Our results demonstrated sequencing of ctDNA provides more thorough information on the genomic instability and is a potential representative biomarker for risk stratification and in newly diagnosed MM than bone marrow. Full article
(This article belongs to the Special Issue Circulating Tumor DNA for Cancer Patient Follow-Up: From Technological to Clinical Perspectives)
►▼ Show Figures

Figure 1

Review

Jump to: Research

28 pages, 949 KiB  
Review
The Position of Circulating Tumor DNA in the Clinical Management of Colorectal Cancer
by Ana Regina de Abreu, Ken Op de Beeck, Pierre Laurent-Puig, Valerie Taly and Leonor Benhaim
Cancers 2023, 15(4), 1284; https://doi.org/10.3390/cancers15041284 - 17 Feb 2023
Cited by 4 | Viewed by 2483
Abstract
Colorectal cancer (CRC) is the third most common cancer type worldwide, with over 1.9 million new cases and 935,000 related deaths in 2020. Within the next decade, the incidence of CRC is estimated to increase by 60% and the mortality by 80%. One [...] Read more.
Colorectal cancer (CRC) is the third most common cancer type worldwide, with over 1.9 million new cases and 935,000 related deaths in 2020. Within the next decade, the incidence of CRC is estimated to increase by 60% and the mortality by 80%. One of the underlying causes of poor prognosis is late detection, with 60 to 70% of the diagnoses occurring at advanced stages. Circulating cell-free DNA (ccfDNA) is probably the most promising tool for screening, diagnosis, prediction of therapeutic response, and prognosis. More specifically, the analysis of the tumor fraction within the ccfDNA (circulating tumor DNA, ctDNA) has great potential to improve the management of CRC. The present review provides an up-to-date and comprehensive overview of the various aspects related to ctDNA detection in CRC. Full article
(This article belongs to the Special Issue Circulating Tumor DNA for Cancer Patient Follow-Up: From Technological to Clinical Perspectives)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop